Dose dependent pharmacokinetics of N‐ACETYLCYSTEINE AFTER ORAL DOSING TO MAN
- 1 March 1990
- journal article
- clinical trial
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 11 (2), 131-136
- https://doi.org/10.1002/bdd.2510110205
Abstract
The pharmacokinetics after oral administration of 200, 600 or 1200 mg of N‐acetylcysteine (NAC) were studied in 10 healthy subjects. Normalized maximal plasma concentration was significantly higher after a 600 mg dose than after a 200 mg dose. Bioavailability of NAC significantly increased with increasing dose. Time for maximal plasma concentration also increased with increasing dose. The observations can be explained by a capacity‐limited presystemic elimination of NAC. In an extension of the study, 600 mg of NAC was given twice a day for 5 days and the plasma concentrations were followed after the morning dose on day 6. No differences in the pharmacokinetic parameters were observed in comparison with the single 600 mg dose. This indicates that the beneficial clinical effects observed after repeated dosing can not be ascribed to an accumulation of NAC in plasma.Keywords
This publication has 5 references indexed in Scilit:
- Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitisEuropean Respiratory Journal, 1988
- Lung Protection by a Thiol-Containing Antioxidant: N-AcetylcysteineRespiration, 1986
- Pharmacokinetics of N-acetylcysteine in manEuropean Journal of Clinical Pharmacology, 1986
- Determination of non-protein-bound N-acetylcysteine in plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1984
- Selective absorption of stereo-isomers of amino-acids from loops of the small intestine of the ratBiochemical Journal, 1951